To study the effects of linagliptin on the structural signs of non-alcoholic fatty liver disease (NAFLD) in Male diabetic In 18-wk-old diabetic mice, liver steatosis (predominantly microvesicular and Show more
To study the effects of linagliptin on the structural signs of non-alcoholic fatty liver disease (NAFLD) in Male diabetic In 18-wk-old diabetic mice, liver steatosis (predominantly microvesicular and mediovesicular steatosis) was accompanied by dilation of the roots of the lymphatic system, interlobular blood vessels and bile canaliculi. Compared to saline-treated mice, linagliptin-treated mice exhibited a reduction in the mean numeral densities of hepatocytes with lipid droplets (92.4% ± 1.7% The DPP4 inhibitor linagliptin alleviates liver steatosis and structural changes in the hepatic microvasculature and lymphatic roots in a model of NAFLD in diabetic Show less